学术探索
学术期刊
新闻热点
数据分析
智能评审

Genome-wide detection of LOH in prostate cancer using human SNP microarray technology

被引：71
作者：
Dumur, CI
Dechsukhum, C
Ware, JL
Cofield, SS
Best, AM
Wilkinson, DS
Garrett, CT
Ferreira-Gonzalez, A [1 ]
机构：
[1] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA
来源：
GENOMICS | 2003年 / 81卷 / 03期
关键词：
LOH; SNP; prostate cancer; genome-wide; oligonucleotide microarray;
D O I：
10.1016/S0888-7543(03)00020-X
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Loss of heterozygosity (LOH) of chromosomal regions is crucial in tumor progression. In this study we assessed the potential of the Affymetrix GeneChip HuSNP mapping assay for detecting genome-wide LOH in prostate tumors. We analyzed two human prostate cell lines, P69SV40Tag (P69) and its tumorigenic subline, M12, and 11 prostate cancer cases. The M 12 cells showed LOH in chromosomes 3p12.1-p22.1, 11q22.1-q24.2, 19p13.12, and 19q13.42. All of the prostate cases with informative single-nucleotide polymorphism (SNP) markers showed LOH in 1p31.2, 10q11.21, 12p13.1, 16q23.1-q23.2, 17p13.3, 17q21.31, and 21q21.2. Additionally, a high percentage of cases showed LOH at 6p25.1-p25.3 (75%), 8p22-p23.2, and 10q22.1 (70%). Several tumor suppressor genes (TSGs) have been mapped in these loci. These results demonstrate that the HuSNP mapping assay can serve as an alternative to comparative genomic hybridization for assessing genome-wide LOH and can identify chromosomal regions harboring candidate TSGs implicated in prostate cancer. (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码：260 / 269
页数：10
相关论文
共 53 条
[1]   Chromosome 5 allelic losses are early events in tumours of the papilla of Vater and occur at sites similar to those of gastric cancer [J].
Achille, A ;
Baron, A ;
Zamboni, G ;
Di Pace, C ;
Orlandini, S ;
Scarpa, A .
BRITISH JOURNAL OF CANCER, 1998, 78 (12) :1653-1660
[2]   Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours [J].
Agathanggelou, A ;
Honorio, S ;
Macartney, DP ;
Martinez, A ;
Dallol, A ;
Radar, J ;
Fullwood, P ;
Chauhan, A ;
Walker, R ;
Shaw, JA ;
Hosoe, S ;
Lerman, MI ;
Minna, JD ;
Maher, ER ;
Latif, F .
ONCOGENE, 2001, 20 (12) :1509-1518
[3]   TUMORIGENICITY OF SV40 T-ANTIGEN IMMORTALIZED HUMAN PROSTATE EPITHELIAL-CELLS - ASSOCIATION WITH DECREASED EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) EXPRESSION [J].
BAE, VL ;
JACKSONCOOK, CK ;
BROTHMAN, AR ;
MAYGARDEN, SJ ;
WARE, JL .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (05) :721-729
[4]  
Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO
[5]  
2-G
[6]   Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma [J].
Baysal, BE ;
Ferrell, RE ;
Willett-Brozick, JE ;
Lawrence, EC ;
Myssiorek, D ;
Bosch, A ;
van der Mey, A ;
Taschner, PEM ;
Rubinstein, WS ;
Myers, EN ;
Richard, CW ;
Cornelisse, CJ ;
Devilee, P ;
Devlin, B .
SCIENCE, 2000, 287 (5454) :848-851
[7]   Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast,testicular, and ovarian cancers [J].
Bharaj, BB ;
Luo, LY ;
Jung, K ;
Stephan, C ;
Diamandis, EP .
PROSTATE, 2002, 51 (01) :35-41
[8]   Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping [J].
Bluteau, O ;
Beaudoin, JC ;
Pasturaud, P ;
Belghiti, J ;
Franco, D ;
Bioulac-Sage, P ;
Laurent-Puig, P ;
Zucman-Rossi, J .
ONCOGENE, 2002, 21 (08) :1225-1232
[9]  
Brown MA, 1997, ADV GENET, V36, P45, DOI 10.1016/S0065-2660(08)60307-7
[10]   MEASURES OF CLINICAL AGREEMENT FOR NOMINAL AND CATEGORICAL-DATA - THE KAPPA COEFFICIENT [J].
CYR, L ;
FRANCIS, K .
COMPUTERS IN BIOLOGY AND MEDICINE, 1992, 22 (04) :239-246
123456